Abbott Laboratories (ABT) Stock Price, News & Analysis

Company Overview

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system. Its diagnostics business provides laboratory and point-of-care testing systems, instruments and assays used to detect and monitor a wide range of medical conditions.

The company’s nutritional products include infant, pediatric and adult nutrition brands such as Similac, Ensure, Glucerna and Pedialyte. Abbott also sells branded generic medicines across several therapeutic areas, with products marketed in numerous countries. Robert B. Ford serves as Abbott’s chairman and chief executive officer.

Key Stats

• Today's Range: $100.26 to $101.47
• 50-Day Range: $99.67 to $116.70
• 52-Week Range: $81.97 to $135.45
• Volume: 3.74 million shs
• Average Volume: 11.41 million shs
• Market Capitalization: $174.80 billion
• P/E Ratio: 32.67
• Dividend Yield: 2.49%
• Price Target: $119.50
• Consensus Rating: Moderate Buy

Abbott Laboratories Stock Analysis - MarketRank™

Abbott Laboratories scored higher than 99% of companies evaluated by MarketBeat, and ranked 3rd out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Abbott Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.96, and is based on 3 strong buy ratings, 20 buy ratings, 4 hold ratings, and no sell ratings.

Upside Potential

Abbott Laboratories has a consensus price target of $119.50, representing about 18.1% upside from its current price of $101.17.

Amount of Analyst Coverage

Abbott Laboratories has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 10.14%

Earnings Growth

Earnings for Abbott Laboratories are expected to grow by 10.14% in the coming year, from $5.52 to $6.08 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Abbott Laboratories is 32.72, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.79.

Price to Earnings Ratio vs. Sector

The P/E ratio of Abbott Laboratories is 32.72, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.98.

Price to Earnings Growth Ratio

Abbott Laboratories has a PEG Ratio of 1.88. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Abbott Laboratories has a P/B Ratio of 3.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.16% of the float of Abbott Laboratories has been sold short.

Short Interest Ratio / Days to Cover

Abbott Laboratories has a short interest ratio ("days to cover") of 2.57, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Abbott Laboratories has recently decreased by 10.03%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Yield

Abbott Laboratories pays a meaningful dividend of 2.49%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Abbott Laboratories has been increasing its dividend for 54 years.

Dividend Coverage

The dividend payout ratio of Abbott Laboratories is 81.55%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, Abbott Laboratories will have a dividend payout ratio of 41.45% next year. This indicates that Abbott Laboratories will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.87

News Sentiment

Abbott Laboratories has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 22 news articles for Abbott Laboratories this week, compared to 10 articles on an average week.

Search Interest

Only 43 people have searched for ABT on MarketBeat in the last 30 days. This is a decrease of -4% compared to the previous 30 days.

MarketBeat Follows

24 people have added Abbott Laboratories to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Abbott Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,958.00 in company stock.

Percentage Held by Insiders

0.46% of the stock of Abbott Laboratories is held by insiders.

Percentage Held by Institutions

75.18% of the stock of Abbott Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 8/17 Dividend: 7/15/2026
• Ex-Dividend for 8/17 Dividend: 7/15/2026
• Last Earnings: 7/16/2026
• Dividend Payable: 8/17/2026
• Today: 9/28/2026
• Record date for 11/16 Dividend: 10/15/2026
• Ex-Dividend for 11/16 Dividend: 10/15/2026
• Next Earnings (Estimated): 10/21/2026
• Dividend Payable: 11/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSE:ABT
• CIK: 1800
• Web: www.abbott.com
• Phone: (224) 667-6100
• Fax: 847-937-1511
• Employees: 115,000
• Year Founded: 1888

Price Target and Rating

• Average Price Target for Abbott Laboratories: $119.50
• High Price Target: $143.00
• Low Price Target: $92.00
• Potential Upside/Downside: +18.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.96
• Research Coverage: 27 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.09
• Trailing P/E Ratio: 32.65
• Forward P/E Ratio: 18.28
• P/E Growth: 1.88
• Net Income: $6.52 billion
• Net Margins: 11.65%
• Pretax Margin: 16.12%
• Return on Equity: 17.69%
• Return on Assets: 9.44%

Debt

• Debt-to-Equity Ratio: 0.57
• Current Ratio: 1.38
• Quick Ratio: 0.97

Sales & Book Value

• Annual Sales: $44.33 billion
• Price / Sales: 3.94
• Cash Flow: $6.96 per share
• Price / Cash Flow: 14.49
• Book Value: $30.35 per share
• Price / Book: 3.32

Miscellaneous

• Outstanding Shares: 1,730,380,000
• Free Float: 1,722,423,000
• Market Cap: $174.56 billion
• Optionable: Optionable
• Beta: 0.59